-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Reiterates Outperform on Edgewise Therapeutics, Maintains $48 Price Target

Benzinga·06/05/2025 14:05:55
Listen to the news
RBC Capital analyst Leonid Timashev reiterates Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and maintains $48 price target.